Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Friday, June 12th. The stock was sold at an average price of $541.39, for a total value of $5,143,205.00. Following the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at $21,933,333.07. This represents a 19.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR traded up $3.61 during mid-day trading on Monday, reaching $549.57. The company had a trading volume of 332,930 shares, compared to its average volume of 478,203. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35. The firm has a market cap of $23.33 billion, a price-to-earnings ratio of 20.29, a PEG ratio of 1.78 and a beta of 0.57. The business’s 50-day simple moving average is $566.75 and its 200 day simple moving average is $521.65.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. During the same quarter in the previous year, the business posted $6.63 EPS. The firm’s revenue for the quarter was down 1.6% on a year-over-year basis. On average, sell-side analysts anticipate that United Therapeutics Corporation will post 26.84 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Geneos Wealth Management Inc. boosted its stake in shares of United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 85 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its stake in shares of United Therapeutics by 18.8% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 70 shares in the last quarter. Jump Financial LLC acquired a new stake in shares of United Therapeutics during the second quarter valued at about $277,000. Cerity Partners LLC boosted its stake in shares of United Therapeutics by 77.3% during the second quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock valued at $3,691,000 after purchasing an additional 5,600 shares in the last quarter. Finally, Bank of Nova Scotia boosted its stake in shares of United Therapeutics by 6.9% during the second quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock valued at $468,000 after purchasing an additional 105 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on UTHR. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research report on Thursday. UBS Group raised their price target on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Bank of America raised their price target on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 31st. Finally, Oppenheimer raised their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $619.42.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.